Reader response: Pimavanserin: A novel therapeutic option for Parkinson disease psychosis
Citation Manager Formats

Hawkins and Berman1 acknowledge limitations to current therapeutic approaches (including medication costs), but underestimate potential negative effects of Parkinson disease psychosis (PDP) on the patient, caregiver, and health care system. PDP may be a harbinger of increased risk of morbidity and mortality, as well as portend admittance to a long-term care facility; these factors ultimately correlate with a surmountable burden on the system and higher cost to the patient over time.
The authors suggest that pimavanserin should be used as a second-line agent to an initial trial of low-dose quetiapine. An efficacious low dose is unlikely, and even at a low dose quetiapine can cause harmful side effects.2 Early use of pimavanserin may be more cost-effective and result in no worsening of motor functions and no reduction in dopaminergic agents.3 Atypical antipsychotics should be second line to pimavanserin when Parkinson disease dementia is not sufficiently controlled.
Pimavanserin should be used as a first-line agent for the treatment of PDP and treatment should be started at symptom onset since PDP progression can be unpredictable. We agree with the Food and Drug Administration's indication for the use of pimavanserin4 given its efficacy data and safety profile and considering the broad side effect profile of the alternative antipsychotic medications.
Footnotes
Author disclosures are available upon request (ncpjournal{at}neurology.org).
- © 2018 American Academy of Neurology
References
- 1.↵
- Hawkins T,
- Berman BD
- 2.↵
- 3.↵
- 4.↵FDA approves first drug to treat hallucinations and delusions associated with Parkinson's disease. Available at: fda.gov/newsevents/newsroom/pressannouncements/ucm498442.htm. Accessed November 8, 2017.
The Nerve!: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.cp.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.